3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 4
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
2
Urothelial Cancer
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pain, Intractable
1
Neoplasms
1
Nausea
1
Liposarcoma
1
Dyspnea
1
Delirium
1
Death
1
Colorectal Neoplasms
1
Choledocholithiasis
1
Choledochal Cyst
1
Cholangitis
1
Adenocarcinoma of Lung
1
Interventions
Docetaxel
137
Prednisone
120
Abiraterone Acetate
91
Leuprolide
86
enzalutamide
84
Radiotherapy
59
bicalutamide
56
Magnetic Resonance Spectroscopy
54
Goserelin
54
Androgen Antagonists
51
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
47
apalutamide
44
abiraterone
34
Radiosurgery
31
Specimen Handling
30
gallium 68 PSMA-11
29
Gonadotropin-Releasing Hormone
29
cabazitaxel
28
Carboplatin
27
darolutamide
25
Estramustine
24
luprolide acetate gel depot
23
relugolix
22
Metformin
22
Triptorelin Pamoate
20
sipuleucel-T
19
radium Ra 223 dichloride
19
Radiation
19
pembrolizumab
18
deltacortene
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled